ArticlePediatric transplantation2025
Factors Influencing 25-Year Survival in Pediatric Liver Transplant Recipients.
Article in Pediatric transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Defining the Society of Pediatric Liver Transplantation (SPLIT) research agenda: A Delphi consensus project.Hepatology communications · 2026Article
- Factors Influencing 25-Year Survival in Pediatric Liver Transplant Recipients.Pediatric transplantation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study assesses the impact of cholestatic liver disease, including biliary atresia, on 25-year survival post-transplantation and additional factors influencing long-term outcomes after pediatric liver transplantation.
methodsWe conducted a retrospective analysis of pediatric liver transplant recipients (1987-1998) using de-identified data from the OPTN 2023 Liver Database. After exclusions for multi-organ transplants (n = 222), prior transplants (n = 2256), and deaths within 1 year (n = 526), 2429 patients remained, including 645 with cholestatic disease. Univariate and multivariate analyses identified factors associated with 25-year survival.
resultsA primary diagnosis of cholestatic disease was associated with improved 25-year survival (OR: 0.67, p = 0.023). UNOS regions 2 (OR: 0.65, p = 0.009) and 5 were also associated with improved survival (OR: 0.72, p = 0.044). Decreased survival was associated with recipient ages 8-12 (OR: 1.84, p = 0.009) and 12-18 (OR: 2.90, p = 0.003), donor age ≥ 19 (OR: 1.42, p = 0.021), African-American (OR: 1.94, p = 0.000) and other minority recipient ethnicities (OR: 2.49, p = 0.018), donor bilirubin ≥ 2 mg/dL (OR: 1.85, p = 0.022), and UNOS region 10 (OR: 1.62, p = 0.009).
conclusionThis study evaluates 25-year survival in pediatric liver transplant recipients while analyzing the protective influence of a cholestatic disease diagnosis. Older recipient and donor ages, minority recipient ethnicities, elevated donor bilirubin, and specific UNOS regions are associated with decreased 25-year survival. Further research is needed to address outcome inequalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.